
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 11/5/2014

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction
of incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02. Results of Operations and Financial Condition

On November 5, 2014, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the third quarter ended September 30, 2014. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated November 5, 2014 titled "Dynavax Reports Third Quarter 2014 Financial Results."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: November 5, 2014

By: /s/ DAVID JOHNSON
David Johnson
Vice President

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press Release, dated November 5, 2014 titled "Dynavax Reports Third Quarter 2014 Financial Results."

Contact:

Michael Ostrach
Chief Business and Principal Financial Officer
510-665-7257
mostrach@dynavax.com

DYNAVAX REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS

BERKELEY, CA – November 5, 2014 – Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2014.

Dynavax had \$130.6 million in cash, cash equivalents and marketable securities as of September 30, 2014, compared to \$154.3 million at June 30, 2014. The net loss for the three months ended September 30, 2014 was \$29.8 million compared to \$24.8 million for the three months ended June 30, 2014. The net loss for the nine months ended September 30, 2014 was \$68.4 million compared to \$53.7 million for the nine months ended September 30, 2013. The increases in net loss are due primarily to increased operating expenses resulting from the phase 3 clinical trial of HEPLISAV-B™ that was initiated in April, 2014. Enrollment in this large safety and immunogenicity study (known as HBV-23) was completed in September, 2014 with more than 8,250 adults, including over 1,100 diabetic patients, enrolled in 40 sites across the U.S. All HBV-23 safety follow up visits are expected to be completed by October, 2015.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

Forward-Looking Statements

This press release contains "forward-looking" statements, including expectations for the conduct, timing and sufficiency of an additional clinical trial for HEPLISAV-B and plans to continue clinical development of AZD1419. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and review and approval of HEPLISAV-B and our process for its manufacture can occur without significant delay or additional studies; whether our studies and manufacturing efforts are sufficient to support registration for commercialization of HEPLISAV-B in either or both of the US and Europe; the timing for and costs of achieving the size of the safety database; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process, including whether a US or European licensure application will be approved; our ability to obtain additional financing to support the development and commercialization of HEPLISAV-B and our other operations; possible claims against us, including enjoining sales of HEPLISAV-B, based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	Three Month Ended September 30,		Nine Months Ended September 30,	
	2014	2013	2014	2013
Revenues:				
Collaboration revenue	\$ 1,795	\$ 1,110	\$ 6,199	\$ 3,349
Grant revenue	414	1,700	2,546	3,855
Service and license revenue	=	117	10	1,200
Total revenues	2,209	2,927	8,755	8,404
Operating expenses:				
Research and development	28,072	11,770	64,942	38,739
General and administrative	4,083	5,807	12,325	22,243
Unoccupied facility expense	131	918	386	918
Total operating expenses	32,286	18,495	77,653	61,900
Loss from operations	(30,077)	(15,568)	(68,898)	(53,496)
Interest income	42	37	162	163
Interest expense	-	(24)	-	(83)
Other income (expense)	216	(120)	300	(248)
Net loss	\$ (29,819)	\$ (15,675)	\$ (68,436)	\$ (53,664)
Basic and diluted net loss per share	\$ (0.11)	\$ (0.09)	\$ (0.26)	\$ (0.29)
Shares used to compute basic and diluted net loss per share				
Shares used to compute basic and diluted net loss per share	262,908	183,022	262,883	182,960

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)

	<u>September 30,</u> <u>2014</u>	<u>December 31,</u> <u>2013</u>
Assets		
Cash, cash equivalents and marketable securities	\$ 130,572	\$ 189,376
Property and equipment, net	8,129	8,706
Goodwill	2,376	2,579
Other assets	<u>5,819</u>	<u>3,961</u>
Total assets	<u>\$ 146,896</u>	<u>\$ 204,622</u>
Liabilities and stockholders' equity		
Deferred revenues	\$ 6,499	\$ 7,298
Other liabilities	<u>18,821</u>	<u>11,030</u>
Total liabilities	25,320	18,328
Stockholders' equity	<u>121,576</u>	<u>186,294</u>
Total liabilities and stockholders' equity	<u>\$ 146,896</u>	<u>\$ 204,622</u>